Evidence map›Paper›PMID 41803488›Full record

ArticleJournal of gastroenterology2026

Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.

Nanae Tsuruoka, Hironobu Takedomi, Yasuhisa Sakata, Shin Fujioka, Ryosuke Sakemi, Shinya Ashizuka, Nobuaki Nishimata, Kazumi Inaba, Shuji Kanmura, Tetsu Kinjo and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nanae TsuruokaDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan. tsuruoka@cc.saga-u.ac.jp.ORCID 0000-0002-5152-5697
Hironobu TakedomiDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan.
Yasuhisa SakataDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan.
Shin FujiokaDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryosuke SakemiDepartment of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyushu, Japan.
Shinya AshizukaDepartment of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Nobuaki NishimataDepartment of Internal Medicine, Junaikai Medical Corporation Sameshima Hospital, Kagoshima, Japan.
Kazumi InabaDepartment of Gastroenterology, Japanese Red Cross Oita Hospital, Oita, Japan.
Shuji KanmuraDigestive and Lifestyle Diseases, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Tetsu KinjoDepartment of Endoscopy, University of the Ryukyus Hospital, Okinawa, Japan.
Yoki FurutaDepartment of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Shinichiro YoshiokaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
Shojiro YamamotoDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Ayako TakamoriClinical Research Center in Hiroshima, Hiroshima University Hospital, Hiroshima, Japan.
Fumihito HiraiDepartment of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Motohiro EsakiDivision of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundScreening and preventive treatment are recommended for latent tuberculosis infection (LTBI) before immunosuppressive therapy in patients with inflammatory bowel disease (IBD). However, the prevalence of LTBI and active tuberculosis, combined with their influence on selection of immunosuppressive therapy, remains uncertain. This retrospective multicenter study aimed to determine the prevalence of LTBI and to evaluate therapeutic management in Japanese patients with IBD according to tuberculosis infection status.

methodsThe clinical profiles and therapeutic management of patients with IBD who were screened for LTBI at any of 10 Japanese institutions between July 2010 and June 2020 were identified by review of the electronic medical records. LTBI was defined as positive when an interferon-gamma release assay or tuberculin test was positive with a normal chest radiograph.

resultsA total of 4257 patients with IBD (Crohn's disease, n = 1646; ulcerative colitis, n = 2611) were included. Sixty-nine patients (1.62%) tested positive for LTBI. Ustekinumab and vedolizumab were used significantly more often in the LTBI group than in the non-LTBI group. Fifty-seven patients (82.6%) in the LTBI group received preventive treatment, while 12 (17.4%) were followed without treatment; only ustekinumab and vedolizumab were selected as advanced therapies. During follow-up, two patients developed active tuberculosis after preventive therapy while receiving immunosuppressive agents.

conclusionsThe prevalence of LTBI among Japanese patients with IBD was 1.62%. Both LTBI status and use of preventive treatment may influence selection of advanced therapies for IBD. Although rare, active tuberculosis can occur despite preventive treatment, highlighting the need for appropriate monitoring strategies.

Indexed as

Immunosuppressive AgentsInflammatory Bowel DiseasesLatent TuberculosisAdultAgedFemaleHumansInterferon-gamma Release TestsJapanMaleMiddle AgedPrevalenceRetrospective StudiesTuberculin TestYoung AdultImmunosuppressive AgentsImmunosuppressive therapyInflammatory bowel diseaseLatent tuberculosis infection

Identifiers

PMID41803488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.